Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

Rahimi, Mehrali; Afjeh, Sara Sadat Aghabozorg; Omrani, Mir Davood; Arsang‐Jang, Shahram; Ganji, Maziar; Noroozi, Rezvan; Ghafouri‐Fard, Soudeh

doi:10.1159/000488622

Cited by 13 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other researchers examined the association between the receptor for advanced glycation end-products (RAGE) and disease-modifying drugs [ 42 ]. Rahimi et al [ 43 ] and Asadikaram et al [ 44 ] noticed elevated levels of serum soluble RAGE in patients treated with interferon β. Moreover, Sternberg et al [ 45 ] observed that fingolimod also mediated modulation of the RAGE axis, which apparently contributed to the anti-inflammatory and neuroprotective effects of fingolimod.…”

Section: Discussionmentioning

confidence: 99%

Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients

Damasiewicz-Bodzek

Łabuz-Roszak

Kumaszka³

et al. 2020

Arch Med Sci

View full text Add to dashboard Cite

IntroductionAdvanced glycation end-products (AGE) are involved in the pathogenesis of many diseases, including neurodegenerative diseases such as multiple sclerosis (MS). The aim of the study was to evaluate the intensity of the protein glycation process in patients with multiple sclerosis and its possible involvement in disease activity.Material and methodsThe study group (n = 45) consisted of patients suffering from MS, and the control group (n = 31) consisted of healthy adults. Concentrations of selected glycation markers such as carboxymethyllysine (CML) and carboxyethyllysine (CEL) in sera of patients with MS and healthy volunteers were determined by enzyme-linked immunosorbent assay (ELISA).ResultsSerum CML and CEL concentrations in patients with MS were higher than in healthy volunteers but only for CML the difference was statistically significant. CML concentrations positively correlated with CEL concentrations only in the healthy persons. In MS patients the serum CML and CEL concentrations did not differ significantly depending on the duration of the disease and depending on the EDSS (Expanded Disability Status Scale) score.ConclusionsMultiple sclerosis is accompanied by an intensification of protein glycation processes, especially within the pathways leading to the formation of carboxymethyllysine. The duration of the disease and the degree of motor impairment do not appear to affect the progression of the glycation processes. However, the disease process associated with multiple sclerosis may affect the relationship between CML and CEL concentrations.

show abstract

Section: Discussionmentioning

confidence: 99%

Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients

Damasiewicz-Bodzek

Łabuz-Roszak

Kumaszka³

et al. 2020

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…[28][29][30] However, in patients with MS who underwent CinnoVex (IFNβ-1a) or fingolimod (sphingosine-1-phosphate receptor modulator) treatments, the levels of soluble RAGE were increased, which corresponded to a positive treatment response, emphasizing the possible role of soluble RAGE in reducing neuroinflammation in affected tissue, thus diminishing the signs and symptoms of the disease. 31,32 Despite the fact that studies on the use of soluble RAGE as a specific marker of ALS progression are still in the early stages, based on evidence derived from our and other recent translational studies demonstrating the involvement of RAGE in the pathogenesis of ALS, we might assume that measuring RAGE level, especially in conjunction with AGE and AOPP, could be a prognostic marker of ALS progression. Our study demonstrated that blocking RAGE signaling with soluble RAGE delays the progression of the disease and slows down the motor function decline.…”

Section: Discussionmentioning

confidence: 97%

Plasma levels of soluble RAGE, AGEs and AOPPs at the early stage of amyotrophic lateral sclerosis: A preliminary study

Juranek,

Osowski,

Wojtkiewicz

et al. 2023

Polim. Med.

View full text Add to dashboard Cite

Background. Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder with largely unknown pathogenesis and no effective cure. It is believed that several, not mutually exclusive mechanisms contribute to the pathogenesis and progression of this disease, including, among others, elevated oxidative stress, excitotoxicity, increased neuroinflammation, and protein aggregation. Receptor for advanced glycation end products (RAGE) is a part of immunoglobulin superfamily; it is believed to participate in ALS pathogenesis. Objectives.Our previous studies on ALS demonstrated that RAGE is likely one of the key players in ALS, acting on its own and in tandem with its oxidative stress and pro-inflammatory ligands, such as advanced glycation end products (AGEs) or advanced oxidation protein products (AOPPs). In this study, based on our previous results, we aimed to establish blood levels of soluble RAGE, AGE and AOPP in ALS patients. Materials and methods.Forty-six coded and anonymized surplus plasma samples from ALS patients and non-neurological control were used in the study. The plasma levels of RAGE, AGE and AOPP were measured using enzyme-linked immunosorbent assay (ELISA) commercially available kits. Statistical evaluation of data was performed using one-way non-parametric analysis of variance (ANOVA) with Kruskal-Wallis post hoc test. Results.Our results revealed a decline in soluble RAGE level, concurrent with an increase in the levels of AGEs and AOPPs in blood samples from ALS patients, signifying a loss of neuroprotective form of RAGE and a simultaneous increase in AGE and AOPP production and uptake at the early stage of the disease. Conclusions.The results obtained from our study indicate that further longitudinal study of RAGE, AGE and AOPP levels would be beneficial, outlining the dynamics between RAGE and its ligand levels as the disease progresses, and making them valuable diagnostic tools and potential therapeutic targets.

show abstract

“…Another investigation by Gholamreza Asadikaram and colleagues in 2016 found that the mRNA expression levels of S100A12 were dramatically lowered in untreated new cases of RRMS 27 . Mahnoosh Rahim's study found that patients treated with interferon 28 had higher levels of S100A12 gene expression 28 .…”

Section: Discussionmentioning

confidence: 98%

Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members

Samangooei

Farjam

Etemadifar

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Multiple sclerosis is an inflammatory disease of the spinal cord and brain. Receptor for advanced glycation end products and Apolipoprotein A1 (Apo-AI) have been recommended to have a pathogenic role in the neuroinflammatory disorder as multiple sclerosis. The purpose of this research was to measure the plasma levels of S100A12 and Apo-A1 in the first-degree family of relapsing–remitting multiple sclerosis (RRMS) patients. Plasma levels of S100A12 & Apo-A1 were evaluated via enzyme-linked immunosorbent assay in the thirty-five new cases of untreated patients with deterministic RRMS according to the McDonald criteria, twenty-four healthy controls, and twenty-six first-degree members of untreated RRMS patients (called them as high-risk group). The main findings of this study were as follows: the plasma level of S100A12 was significantly lower in the new cases of untreated RRMS (P ≤ 0.05; 0.045) and high-risk (P ≤ 0.05; 0.001) groups. Although the plasma protein level of Apo-A1 was reduced significantly in the high-risk group (P < 0.05, P = 0.003) as compared to the healthy control group, there was no significant difference in the untreated RRMS patients (P = 0.379). The plasma level of vitamin D3 in both RRMS patients and high-risk groups displayed significance reduction, although, there was no significant association between vitamin D and S100A12 & Apo-A1 levels. Given the role of S100A12 and Apo-A1 in the inflammatory process performed in the first-degree family members of the RRMS patients, which revealed a significant decrease in this group, we concluded that they can be considered as one of the contributing factors in the pathogenesis of MS, though more research is needed before assuming them as predictive biomarkers.

show abstract

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

Cited by 13 publications

References 20 publications

Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients

Carboxymethyllysine and carboxyethyllysine in multiple sclerosis patients

Plasma levels of soluble RAGE, AGEs and AOPPs at the early stage of amyotrophic lateral sclerosis: A preliminary study

Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members

Contact Info

Product

Resources

About